• Users Online: 517
  • Print this page
  • Email this page

 Table of Contents  
Year : 2017  |  Volume : 7  |  Issue : 2  |  Page : 59-61

Therapy for Amblyopia: A newer perspective

Department of Ophthalmology, Shu-Tien Urology Ophthalmology Clinic, The Yin Shu-Tien Medical Foundation; Department of Ophthalmology, Taipei Veterans General Hospital; Department of Ophthalmology, School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China

Date of Web Publication20-Jun-2017

Correspondence Address:
May-Yung Yen
Department of Ophthalmology, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 11217
Republic of China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/tjo.tjo_56_17

Rights and Permissions

How to cite this article:
Yen MY. Therapy for Amblyopia: A newer perspective. Taiwan J Ophthalmol 2017;7:59-61

How to cite this URL:
Yen MY. Therapy for Amblyopia: A newer perspective. Taiwan J Ophthalmol [serial online] 2017 [cited 2019 Dec 16];7:59-61. Available from: http://www.e-tjo.org/text.asp?2017/7/2/59/208587

Amblyopia is a reduction of best-corrected visual acuity that cannot be contributed to the structural abnormality of the eye. The prevalence of amblyopia is between 2% and 5%.[1] Amblyopia is associated most commonly with early childhood strabismus and anisometropia and less commonly with ametropia and vision deprivation such as congenital cataract.

The conventional treatments for amblyopia include refractive correction, occlusion, and atropine penalization. Optimal refractive correction alone can resolve in at least one-third of cases with untreated anisometropic amblyopia and even some untreated strabismic amblyopia.[2] If amblyopia is not resolved, occlusion or pharmacological penalization with atropine on the better eye is often prescribed simultaneously or soon after refractive correction is provided.

Even with spectacle correction plus occlusion or atropine penalization, there are still one-third of amblyopia have poor response to treatment. Eyes with poor initial visual acuity, the presence of significant astigmatism, and age of over 6 years are risk factors of treatment failure.[3] Compliance with amblyopia treatments has a major effect on response to therapy.

Compliance of conventional amblyopic treatment is generally low. Discomfort from eye patches, difficulties with vision from occluding the better eye, psychological distress, uncomfortable effect of bright sunlight to the atropine-treated eye, and ocular sensitivity to atropine are the causes of poor compliance.[4]

  Reduced Connectivity between Brain Areas Top

Recent studies have shown that the physiological basis of amblyopia is mainly located at visual cortex and lateral geniculate nucleus. Functional magnetic resonance imaging study in human amblyopia suggests that V1 may be the earliest anatomic site in the visual pathway.[5],[6] Optimized voxel-based morphometry indicates that human amblyopes have reduced gray matter volume in visual cortical region.[7] Amblyopic deficit not only involves circumscribed visual areas as visual cortex and lateral geniculate nucleus but also reduced the effective connectivity in different visual areas.[8] The effective connectivity loss was found correlated with the degree of amblyopia. Feedforward and feedback connectivities are similarly affected.

  Plasticity of Visual System Top

The effect of treatment for amblyopia usually decreases after critical period which is thought to be 6 years of age and is thought attributing to decreased brain plasticity.

The plasticity of visual system is greatest in early infancy. It is triggered by maturation of inhibitory, gamma-aminobutyric acid (GABA)-producing interneurons.[9] In amblyopes, there is suppression from the better-seeing eye over the amblyopic eye.[10] GABA is thought to play a key role in suppression of inputs from the amblyopic eye within the visual cortex.

  The Role of Suppression in Amblyopia Top

Early concept think that suppression simply follows amblyopia. Treatments of amblyopia focus on occlusion or penalization of the better eye because the input from the amblyopic eye is weaker. The treatment does not concern suppression. The current concept thinks that suppression plays the causal role in amblyopia. Disruption of binocular function causes suppression leading to amblyopia.

Using dichoptic motion coherence threshold technique,[11] quantitative measurement of interocular suppression is assessed in strabismic and anisometropic amblyopia. It is found that deeper suppression is associated with poorer vision in the amblyopic eye.

Due to limited success of conventional treatment for amblyopia and the new concept of brain plasticity, a variety of treatment strategies were investigated. These include dichoptic treatments and pharmacological therapy.

  Dichoptic Treatment Top

Suppressive interactions within the visual cortex are a viable target for amblyopia treatment. Theory of dichoptic training bases on the concept that the binocular circuitry from the weak amblyopic eye is actively suppressed by the strong fellow eye.[12] Dichoptic training tasks reduce fellow eye contrast to rebalance the contrast between the eyes. Dichoptic treatment of amblyopia promotes binocular vision and reduces inhibitory interactions within the visual cortex. Reduce suppression within the visual cortex was found enhancing improvements in binocular visual function in adult amblyopes. Repeated exposures to dichoptic motion coherence threshold stimuli effectively reduce suppression in adults with amblyopia, which in turn improve visual acuity and stereopsis. These visual improvements are sustained and have so far been demonstrated in adults well beyond the critical period of visual development.

Behavioral treatments including perceptual learning, dichoptic training, and video game are found improving visual function in adult amblyopia. A meta-analysis found that these new methods yielded a mean improvement of visual acuity of 0.17 logMAR with 32% of patients achieving gains ≥0.2 logMAR.[13]

Although dichoptic amblyopic therapy shows significant visual improvement in children and adult amblyopic patient, there is no home-based dichoptic training design and most of the training needs a supervisor.[14] No long-term comparison of conventional occlusion treatment and dichoptic treatment has been studied. Design of home-based dichoptic amblyopic treatment with long-term randomized control trial needs further investigation.

  Pharmacological Treatment Top

In this issue, Singh et al. reviewed studies on pharmacological therapy for amblyopia. The drugs in this review include levodopa-carbidopa combination and antidepressants such as fluoxetine, GABA antagonists, and cytidine 5'-diphosphocholine (choline or citicoline).

The effect of levodopa was studied on many aspects. It can increase endogenous expression of nerve growth factor, increase expression of N-methyl-D-aspartate receptor-1-subunit in visual cortical neurons which is reduced in amblyopia, improve visual evoked potential response, increase visual acuity, and decrease fixation point scotomas.

Chronic administration of fluoxetine promotes the recovery of visual functions in adult amblyopic animals by reducing the intracortical inhibition and increasing the expression of brain-derived neurotrophic factor in the visual cortex.

GABA antagonist was found able to restore binocularity. However, it also has serious adverse effect. Significant visual improvement was found in citicoline administration.

However, most of these drugs are still in experimental stage. Further evaluations of efficacy and side effect of these drugs are needed.

  References Top

Preslan MW, Novak A. Baltimore vision screening project. Phase 2. Ophthalmology 1998;105:150-3.  Back to cited text no. 1
Cotter SA, Edwards AR, Arnold RW, Astle WF, Barnhardt CN, Beck RW, et al. Treatment of strabismic amblyopia with refractive correction. Am J Ophthalmol 2007;143:1060-3.  Back to cited text no. 2
Hussein MA, Coats DK, Muthialu A, Cohen E, Paysse EA. Risk factors for treatment failure of anisometropic amblyopia. J AAPOS 2004;8:429-34.  Back to cited text no. 3
Wang J. Compliance and patching and atropine amblyopia treatments. Vision Res 2015;114:31-40.  Back to cited text no. 4
Hess RF, Thompson B, Gole G, Mullen KT. Deficient responses from the lateral geniculate nucleus in humans with amblyopia. Eur J Neurosci 2009;29:1064-70.  Back to cited text no. 5
Barnes GR, Hess RF, Dumoulin SO, Achtman RL, Pike GB. The cortical deficit in humans with strabismic amblyopia. J Physiol 2001;533(Pt 1):281-97.  Back to cited text no. 6
Mendola JD, Conner IP, Roy A, Chan ST, Schwartz TL, Odom JV, et al. Voxel-based analysis of MRI detects abnormal visual cortex in children and adults with amblyopia. Hum Brain Mapp 2005;25:222-36.  Back to cited text no. 7
Li X, Mullen KT, Thompson B, Hess RF. Effective connectivity anomalies in human amblyopia. Neuroimage 2011;54:505-16.  Back to cited text no. 8
Tailor VK, Schwarzkopf DS, Dahlmann-Noor AH. Neuroplasticity and amblyopia: Vision at the balance point. Curr Opin Neurol 2017;30:74-83.  Back to cited text no. 9
Sengpiel F, Jirmann KU, Vorobyov V, Eysel UT. Strabismic suppression is mediated by inhibitory interactions in the primary visual cortex. Cereb Cortex 2006;16:1750-8.  Back to cited text no. 10
Li J, Hess RF, Chan LY, Deng D, Yang X, Chen X, et al. Quantitative measurement of interocular suppression in anisometropic amblyopia: A case-control study. Ophthalmology 2013;120:1672-80.  Back to cited text no. 11
Li J, Thompson B, Lam CS, Deng D, Chan LY, Maehara G, et al. The role of suppression in amblyopia. Invest Ophthalmol Vis Sci 2011;52:4169-76.  Back to cited text no. 12
Tsirlin I, Colpa L, Goltz HC, Wong AM. Behavioral training as new treatment for adult amblyopia: A meta-analysis and systematic review. Invest Ophthalmol Vis Sci 2015;56:4061-75.  Back to cited text no. 13
Foss AJ. Use of video games for the treatment of amblyopia. Curr Opin Ophthalmol 2017;28:276-81.  Back to cited text no. 14

This article has been cited by
1 Conceptualización integral de la ambliopía
Esteban Goñi-Boza,Rebeca Ortiz Barrantes
Ciencia y Tecnología para la Salud Visual y Ocular. 2018; 16(2): 91
[Pubmed] | [DOI]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Dichoptic Treatment
Pharmacological ...
Plasticity of Vi...
The Role of Supp...
Reduced Connecti...

 Article Access Statistics
    PDF Downloaded284    
    Comments [Add]    
    Cited by others 1    

Recommend this journal